把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注，缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存；每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR，A 股链接巨潮原始 PDF，港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性，不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查；超出容差的记录保留原值并标记警告， 不会为了让公式“对上”而修改公司披露。
| 2026-06-30 |
| 3/3 |
| $11.1B |
| $668M |
| — |
| 21.3% |
| 5.9% |
| 28 |
| 尚无授权文本 |
| NVCR NovoCure Ltd | 2026-06-30 | 3/3 | $183.58M | -$15.66M | $1.22M | 77.6% | -5.8% | 105 | 尚无授权文本 |
| THG HANOVER INSURANCE GROUP, INC. | 2026-06-30 | 3/3 | $1.73B | $191.6M | $324.7M | — | 14.6% | 82 | 尚无授权文本 |
| NG NOVAGOLD RESOURCES INC | 2026-05-31 | 3/3 | $0 | -$25.49M | — | — | — | 103 | 尚无授权文本 |
| ALOT AstroNova, Inc. | 2026-04-30 | 3/3 | $39.36M | $653,000 | $2.99M | 36.6% | 4.0% | 91 | 尚无授权文本 |
| ENVX Enovix Corp | 2026-04-05 | 3/3 | $7.6M | -$38.26M | -$36.29M | 20.4% | -577.6% | 98 | 尚无授权文本 |
| ENOV Enovis CORP | 2026-04-03 | 3/3 | $589.15M | -$8.76M | -$28.85M | 62.0% | 1.1% | 94 | 尚无授权文本 |
| NOVT NOVANTA INC | 2026-04-03 | 3/3 | $257.71M | $21.1M | $47.47M | 44.1% | 10.7% | 86 | 尚无授权文本 |
| NOVTU NOVANTA INC | 2026-04-03 | 3/3 | $257.71M | $21.1M | $47.47M | 44.1% | 10.7% | 86 | 尚无授权文本 |
| ANVS Annovis Bio, Inc. | 2026-03-31 | 3/3 | $0 | -$17.61M | — | — | — | 99 | 尚无授权文本 |
| HNVR Hanover Bancorp, Inc. /MD | 2026-03-31 | 3/3 | — | $1.87M | -$2.7M | — | — | 76 | 尚无授权文本 |
| IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC | 2026-03-31 | 3/3 | $69M | $32.81M | — | — | 47.7% | 114 | 尚无授权文本 |
| IMVT Immunovant, Inc. | 2026-03-31 | 3/3 | — | -$505.61M | -$407.32M | — | — | 88 | 尚无授权文本 |
| INNV InnovAge Holding Corp. | 2026-03-31 | 3/3 | $251.94M | -$29.46M | $33.38M | 24.2% | -11.5% | 75 | 尚无授权文本 |
| INO INOVIO PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$19.68M | -$21.59M | — | — | 75 | 尚无授权文本 |
| INVA Innoviva, Inc. | 2026-03-31 | 3/3 | $97.99M | $186.6M | $34.79M | 77.4% | 38.9% | 81 | 尚无授权文本 |
| INVX Innovex International, Inc. | 2026-03-31 | 3/3 | $239.03M | -$16.67M | — | 35.4% | -9.1% | 83 | 尚无授权文本 |
| ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 2026-03-31 | 3/3 | — | $3.43M | $7.72M | — | — | 89 | 尚无授权文本 |
| LIVN LivaNova PLC | 2026-03-31 | 3/3 | $362.26M | $22.29M | $926,000 | 67.3% | 11.4% | 96 | 尚无授权文本 |
| LUCY Innovative Eyewear Inc | 2026-03-31 | 3/3 | $773,561 | -$2.31M | — | 22.7% | — | 49 | 尚无授权文本 |
| MNOV MEDICINOVA INC | 2026-03-31 | 3/3 | $186,984 | -$2.59M | -$3.48M | — | -1516.6% | 46 | 尚无授权文本 |
| NKLR Terra Innovatum Global N.V. | 2026-03-31 | 3/3 | — | -$7.11M | — | — | — | 15 | 尚无授权文本 |
| NNVC NANOVIRICIDES, INC. | 2026-03-31 | 3/3 | — | -$1.99M | -$5.66M | — | — | 50 | 尚无授权文本 |
| NOV NOV Inc. | 2026-03-31 | 3/3 | $2.05B | $19M | -$91M | 18.5% | 2.3% | 80 | 尚无授权文本 |
| NVAX NOVAVAX INC | 2026-03-31 | 3/3 | $139.51M | -$9.49M | — | 78.0% | -11.1% | 137 | 尚无授权文本 |
| ONTO ONTO INNOVATION INC. | 2026-03-31 | 3/3 | $291.95M | $33.75M | $22.74M | 50.1% | 11.5% | 84 | 尚无授权文本 |
| PRPL Purple Innovation, Inc. | 2026-03-31 | 3/3 | $95.73M | -$30.54M | $1.38M | 36.8% | -17.6% | 134 | 尚无授权文本 |
| RNXT RenovoRx, Inc. | 2026-03-31 | 3/3 | $563,000 | -$3.52M | -$3.71M | 85.1% | -616.2% | 71 | 尚无授权文本 |
| SI SHOULDER INNOVATIONS, INC. | 2026-03-31 | 3/3 | $16.71M | -$8.38M | -$15.09M | 77.7% | -53.7% | 15 | 尚无授权文本 |
| SSII SS Innovations International, Inc. | 2026-03-31 | 3/3 | $11.1M | -$3.58M | -$2.37M | 48.0% | -32.8% | 126 | 尚无授权文本 |
| TKNO Alpha Teknova, Inc. | 2026-03-31 | 3/3 | $11.08M | -$4.56M | -$3.58M | 34.2% | -38.8% | 57 | 尚无授权文本 |
| VATE INNOVATE Corp. | 2026-03-31 | 3/3 | $364.8M | -$16.8M | — | 14.7% | 2.7% | 141 | 尚无授权文本 |
| FBIN Fortune Brands Innovations, Inc. | 2026-03-28 | 3/3 | $1.01B | $24.2M | -$139.5M | 43.1% | 6.0% | 92 | 尚无授权文本 |
| BNS BANK OF NOVA SCOTIA | 2026-01-31 | 2/3 | — | $2.3B | — | — | — | 41 | 尚无授权文本 |
| CVE CENOVUS ENERGY INC. | 2025-12-31 | 2/3 | — | $3.93B | — | — | — | 163 | 尚无授权文本 |
| FOFO Hang Feng Technology Innovation Co., Ltd. | 2025-12-31 | 3/3 | $2.33M | -$9.59M | -$1.29M | — | -418.9% | 7 | 尚无授权文本 |
| INVZ Innoviz Technologies Ltd. | 2025-12-31 | 3/3 | $55.09M | -$67.8M | -$52.17M | 23.4% | -123.0% | 79 | 尚无授权文本 |
| NBP NovaBridge Biosciences | 2025-12-31 | 3/3 | — | -$46.27M | — | — | — | 148 | 尚无授权文本 |
| NVMI NOVA LTD. | 2025-12-31 | 3/3 | $880.58M | $259.22M | $217.92M | 57.4% | 28.8% | 155 | 尚无授权文本 |
| NVO NOVO NORDISK A S | 2025-12-31 | 2/3 | — | $102.43B | — | — | — | 491 | 尚无授权文本 |
| NVS NOVARTIS AG | 2025-12-31 | 2/3 | — | $13.97B | — | — | — | 92 | 尚无授权文本 |
| NVX NOVONIX Ltd | 2025-12-31 | 2/3 | — | -$92.73M | — | — | — | 282 | 尚无授权文本 |
| PAVS Paranovus Entertainment Technology Ltd. | 2025-09-30 | 3/3 | $12.41M | -$680,952 | — | 20.0% | -5.1% | 80 | 尚无授权文本 |
| NVA Nova Minerals Corp | 2025-06-30 | 2/3 | — | -$11.1M | — | — | — | 116 | 尚无授权文本 |
| IBG Innovation Beverage Group Ltd | 2024-12-31 | 3/3 | $2.93M | -$2.57M | -$1.58M | 76.1% | -109.1% | 32 | 尚无授权文本 |
| VCX Fundrise Innovation Fund, LLC | — | 0/3 | — | — | — | — | — | 1 | 尚无授权文本 |